Document is current
Any future updates will be listed below
-
Authors
Tetteh, Emmanuel K. https://orcid.org/0000-0002-7892-5914
Effah, William
Fuentes, Lisa de las
Steger-May, Karen
Goss, Charles W.
Dowdy, David W.
Huffman, Mark D.
Williams, Makeda J.
Tonwe, Veronica
Bansal, Geetha P.
Geng, Elvin H.
Dávila-Román, Victor G.
Rice, Treva
Schechtman, Kenneth B
-
Funding
Funding for this research was provided by:
National Heart, Lung, and Blood Institute (U24HL154426)
- License Information
-
More Information
Article History
Received: 24 January 2024
Accepted: 28 May 2024
First Online: 6 June 2024
Declarations
:
: Not Applicable.
: Not applicable.
: MDH has received travel support from the World Heart Federation and consulting fees from PwC Switzerland. MDH has an appointment at The George Institute for Global Health, which has a patent, license, and has received investment funding with intent to commercialize fixed-dose combination therapy through its social enterprise business, George Medicines. MDH has pending patents for heart failure polypills. Elvin Geng is as Associate Editor for Implementation Science Communications.
